Diseases / Gastroparesis
Gastroparesis
DiseaseGastroparesis is a disorder of delayed gastric emptying in which the stomach slows or stops movement of food to the small intestine without mechanical obstruction. It can cause nausea, vomiting, bloating, early satiety, and nutritional complications. Common associations include diabetes and vagus-nerve injury after upper GI surgery.
- Trials
- 290
- Recruiting
- 39
- Completed
- 129
- With results
- 55
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 3 | — | — | — | — | — | — | 4 |
| Phase 1 | — | — | — | — | 12 | — | — | — | — | — | — | 12 |
| Phase 1/2 | — | — | — | — | 3 | — | — | — | 1 | — | — | 4 |
| Phase 2 | — | — | — | — | 30 | 8 | 2 | — | 3 | — | — | 43 |
| Phase 2/3 | 1 | — | — | — | 2 | — | — | — | — | — | — | 3 |
| Phase 3 | 2 | — | — | — | 5 | 5 | 1 | 1 | 3 | — | — | 17 |
| Phase 4 | — | — | — | — | 3 | 6 | 1 | — | — | — | — | 10 |
| Not applicable | 14 | 5 | — | 5 | 48 | 13 | 11 | 1 | 16 | — | — | 113 |
| Unknown | 21 | 5 | 3 | 4 | 23 | 4 | — | — | 17 | 1 | 6 | 84 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Gastroparesis | 4 | 12 | 4 | 43 | 3 | 17 | 10 | 113 | 84 | 290 |
| Vomiting | — | 1 | 1 | 4 | — | 8 | 1 | 10 | 12 | 37 |
| Diabetes Mellitus | — | 2 | 1 | 10 | 2 | 8 | 3 | 5 | 3 | 34 |
| Nausea | — | 1 | 1 | 3 | — | 6 | 1 | 9 | 9 | 30 |
| Dyspepsia | — | — | — | 1 | — | 1 | — | 8 | 4 | 14 |
| Gastroesophageal Reflux | — | — | — | 3 | — | 1 | 1 | 3 | 6 | 14 |
| Digestive System Diseases | — | — | — | 1 | — | 1 | 1 | 3 | 5 | 11 |
| Gastrointestinal Diseases | — | — | — | 1 | — | — | 1 | 1 | 7 | 10 |
| Pancreatic Neoplasms | — | — | — | 1 | — | — | — | 6 | 3 | 10 |
| Diabetes Mellitus, Type 1 | — | 1 | — | 2 | — | — | — | 4 | 1 | 8 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Indiana University | 14 | 0 |
| 2 | GlaxoSmithKline | 11 | 0 |
| 3 | Johns Hopkins University | 10 | 0 |
| 4 | Mayo Clinic | 10 | 1 |
| 5 | Johns Hopkins Bloomberg School of Public Health | 9 | 0 |
| 6 | Allergan | 6 | 5 |
| 7 | Tranzyme, Inc. | 6 | 0 |
| 8 | University of Louisville | 6 | 0 |
| 9 | Cairn Diagnostics | 5 | 0 |
| 10 | Stanford University | 5 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Domperidone | 13 |
| 2 | Pyloromyotomy | 10 |
| 3 | N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine | 9 |
| 4 | relamorelin | 8 |
| 5 | Metoclopramide | 4 |
| 6 | Pancreaticoduodenectomy | 4 |
| 7 | Acupuncture Therapy | 3 |
| 8 | Endoscopy | 3 |
| 9 | Erythromycin | 3 |
| 10 | Gastroscopy | 3 |
Evidence
- Results reported
- 42.6%55 of 129 completed
- Published
- 19.4%25 of 129 completed
- Primary endpoint met
- 38.5%15 of 39 analyses
- Median months to report
- 15
Documents disclosed
Trial profile
- Median enrollment
- 50
- Median duration
- 27.1months
- Countries
- 47
- Study sites
- 1696
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 13
- Phase 1
- 19
- Phase 1/2
- 28
- Phase 2
- 79
- Phase 2/3
- 15
- Phase 3
- 200
- Phase 4
- 28
- Not applicable
- 40
- Unknown
- 100
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Louisville | United States | 33 |
| 2 | Philadelphia | United States | 32 |
| 3 | Boston | United States | 30 |
| 4 | Indianapolis | United States | 26 |
| 5 | Winston-Salem | United States | 26 |
| 6 | El Paso | United States | 23 |
| 7 | Miami | United States | 23 |
| 8 | Houston | United States | 22 |
| 9 | Kansas City | United States | 22 |
| 10 | Jackson | United States | 16 |
Terminations
- Terminated
- 36
- Withdrawn
- 15
- Suspended
- 2
- Stopped for recruitment
- 2.4%7 of 290 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05079568 Suspended | Suspended | Pending funding | 2026-12-31 |
| NCT04287647 Terminated | Terminated | Excessive stent migration. | 2026-05-27 |
| NCT00568373 Withdrawn | Withdrawn | this is not a clinical trial and does not require registration | 2025-12-31 |
| NCT05405842 Withdrawn | Withdrawn | There were equipment issues with the vendor that could not be resolved; therefore, enrollment was never opened. | 2025-09-30 |
| NCT03896126 Terminated | Terminated | Study was stopped due to technical issues with the ANSAR equipment, lack of research personnel caused by COVID-19 restrictions imposed at our site, and recent departure of the PI and study chair from our research institute. | 2025-08-18 |
| NCT06173336 Withdrawn | Withdrawn | Study never started | 2025-06-17 |
| NCT04869670 Terminated | Terminated | Inability to recruit patients for Sham controlled study; therefore, the study was terminated | 2025-03-03 |
| NCT05229107 Withdrawn | Withdrawn | Both Co-PI, Dr. Ken Koch and Dr. Rajeski, have both left the institution, so we have not been able to receive referrals since their departure. | 2024-03-07 |
| NCT04844190 Withdrawn | Withdrawn | Unable to complete study procedures due to staffing issues. | 2024-03-01 |
| NCT03500354 Withdrawn | Withdrawn | PI moved to another institution and closed the study. | 2024-01-31 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: